Literature DB >> 27065430

Proptosis Reduction Using Sirolimus in a Child With an Orbital Vascular Malformation and Blue Rubber Bleb Nevus Syndrome.

Juliana R Gildener-Leapman1, Jamie B Rosenberg, Anne Barmettler.   

Abstract

A 15-month-old boy with left congenital proptosis presented to the emergency department with melena. Upper GI endoscopy and magnetic resonance angiography revealed vascular lesions, consistent with gastrointestinal tract manifestations of blue rubber bleb nevus syndrome. MRI revealed vascular malformations in both orbits, with mass effect on the left side. The patient was started on a trial of the antiangiogenic agent sirolimus (also known as rapamycin), and after 6 months of treatment showed clinical improvement in proptosis supported by radiologic evidence of regression in the larger, left orbital mass, with stability of the smaller, right orbital mass. There are 11 published cases of orbital blue rubber bleb nevus syndrome in the English literature. To our knowledge, this is the first reported case of successful, long-term treatment with sirolimus causing a reduction in the size of an orbital vascular malformation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27065430     DOI: 10.1097/IOP.0000000000000692

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  3 in total

1.  Clinical Assessment and Lesion-Specific Management of Orbital Vascular Malformations.

Authors:  Daniel B Rootman; Stefania B Diniz; Liza M Cohen
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-23

Review 2.  [Clinical effect of sirolimus in treatment of blue rubber bleb nevus syndrome in children: a report of 2 cases and literature review].

Authors:  Xu Quan; Chun-Di Xu; Ping Liu; Qing-Qing Zhang; Ye Chen; Le Wang; Yuan Xiao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-09

3.  Subconjunctival Hemorrhage in a Child with the Blue Rubber Bleb Nevus Syndrome on Treatment with Oral Propranolol.

Authors:  Karen De Loecker; Veerle Labarque; Hilde Seynaeve; Ingele Casteels
Journal:  Case Rep Ophthalmol       Date:  2021-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.